Trigger Point – Self-medication: Patients in white coats
•
3 likes•1,170 views
This document summarizes the key points from a presentation on self-medication given at the Pharmacon 2007 European Congress. The presentation covered: - The structure of the pharmaceutical market and definitions of prescription vs non-prescription medicines - Results from a study on consumer attitudes towards purchasing self-medication products at pharmacies across Europe - Areas of cooperation between industry groups representing manufacturers of non-prescription medicines and pharmacist/medical doctor organizations - The economic and public health value of self-medication - The future role of pharmacists in supporting self-care and recommendations around pharmacy design, education, and visibility of non-prescription products.
Report
Share
Report
Share
Recommended
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Education - Do we have a choice?
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
EPSA Vision Of Pharmacy
The document discusses the European Pharmacy Students' Association (EPSA) and its vision for pharmacy education. EPSA represents over 120,000 pharmacy students across 32 countries. It conducted surveys that found students want more practical teaching methods and flexibility in pharmacy education. EPSA aims to encourage lifelong learning among students and pharmacists to keep their skills and knowledge up to date.
Quo Vadis EU Pharmacy?
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
BY HELPING PEOPLE MY DREAM IS BECOMING TRUE
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Focussing on cytotoxic treatment alone is not enough
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Patient involvement
This document discusses patient involvement at the Medicines Evaluation Board (MEB) in the Netherlands. It makes three key points:
1. The MEB focuses on involving patients throughout the entire life cycle of a medicinal product to ensure the patient perspective is considered. Meetings are held 3-4 times per year and minutes are published online.
2. Strategies for patient involvement at the MEB include having a board member represent the patient perspective, consulting patient organizations on regulatory decisions and guidelines, and creating an online portal for patients.
3. Eliciting individual patient preferences could help identify subgroups with similar preferences to better tailor regulatory decisions and highlight situations where regulator and patient values differ requiring improved communication.
Using Technology to Increase Medication Adherence
Medication Adherence is a pressing issue in the healthcare setting. New advances in technology using mobile apps and smart devices are now changing the way we approach assessing patients medication adherence. However, this shift also allows a new chance to be engaged with patients regarding their medications and offers the opportunity to be more aware of medication related issues.
Recommended
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Education - Do we have a choice?
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
EPSA Vision Of Pharmacy
The document discusses the European Pharmacy Students' Association (EPSA) and its vision for pharmacy education. EPSA represents over 120,000 pharmacy students across 32 countries. It conducted surveys that found students want more practical teaching methods and flexibility in pharmacy education. EPSA aims to encourage lifelong learning among students and pharmacists to keep their skills and knowledge up to date.
Quo Vadis EU Pharmacy?
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
BY HELPING PEOPLE MY DREAM IS BECOMING TRUE
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Focussing on cytotoxic treatment alone is not enough
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Patient involvement
This document discusses patient involvement at the Medicines Evaluation Board (MEB) in the Netherlands. It makes three key points:
1. The MEB focuses on involving patients throughout the entire life cycle of a medicinal product to ensure the patient perspective is considered. Meetings are held 3-4 times per year and minutes are published online.
2. Strategies for patient involvement at the MEB include having a board member represent the patient perspective, consulting patient organizations on regulatory decisions and guidelines, and creating an online portal for patients.
3. Eliciting individual patient preferences could help identify subgroups with similar preferences to better tailor regulatory decisions and highlight situations where regulator and patient values differ requiring improved communication.
Using Technology to Increase Medication Adherence
Medication Adherence is a pressing issue in the healthcare setting. New advances in technology using mobile apps and smart devices are now changing the way we approach assessing patients medication adherence. However, this shift also allows a new chance to be engaged with patients regarding their medications and offers the opportunity to be more aware of medication related issues.
HTA in France
The document discusses HTA processes in France for evaluating new medicines. The French HTA process involves evaluating clinical value (SMR), clinical added value (ASMR), target population size, cost-effectiveness and budget impact. Medicines can receive reimbursement from the national health fund based on these evaluations. The HTA process aims to reward medicines providing real medical progress based on improved efficacy, safety or convenience compared to existing options (ASMR) and being worth their cost (cost-effectiveness).
Rational use of medicine
Rational use of medicine aims to ensure patients receive appropriate medications based on their needs. Irrational use can occur when there is polypharmacy, unnecessary or incorrect medications, underuse of effective medicines, or unsafe drug use. This presentation identifies factors contributing to irrational use at the international, national, health systems, prescriber, dispensing, and patient levels. These include issues like drug promotion, regulations, infrastructure, education and adherence. Strategies to improve rational use involve educational programs for prescribers and patients, management techniques, economic approaches, and regulatory policies like essential drug lists and multi-disciplinary oversight bodies.
ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...
The document discusses using patient-reported outcome measures like health-related quality of life (HRQoL) to evaluate the benefits of drug therapy from the patient's perspective. While traditionally outcomes were measured clinically, there is a shift towards considering how patients feel treatment impacts their daily lives. The document outlines challenges in defining what constitutes a clinically significant change in HRQoL and proposes further refining measures and educating clinicians on appropriate HRQoL data use.
From Laboratory to Patient
This document outlines the process for providing scientific advice to medicine developers through the European Medicines Agency (EMA). It describes the following key steps:
1. Medicine developers submit questions to EMA regarding their medicine development plans. Experts from EMA and national regulators form teams to address the questions.
2. The teams provide responses and advice to help developers design studies that will generate robust evidence on a medicine's safety and effectiveness. This advice is non-binding and does not guarantee approval.
3. The advice aims to help developers avoid poorly-designed trials and instead generate strong data to support regulatory approval and access for patients. It can also encourage development of needed new medicines.
Vi-Med tool for medication review - Form 3 - English version
This document describes various types of drug-related problems (DRPs) that can occur in patient care. It lists and provides examples of unnecessary indication, non-conformity indication, missing indication, inappropriate dosage, improper administration mode, drug side effects, drug interactions, and insufficient drug monitoring. The document appears to be a form or checklist for pharmacists to document a DRP identified in a patient, the pharmacist's intervention to address it, and any follow-up on the outcome of the intervention.
Law update, march 2011
This document summarizes recent legal issues affecting the practice of pharmacy in North Carolina. It discusses proposed state bills on pharmacy technician responsibilities in hospitals and pharmacist vaccination authority. It also outlines recent statutes on drug donation programs and upcoming elections for the North Carolina Board of Pharmacy.
Clinical literature evaluation
This document discusses the importance of evaluating clinical literature and provides guidance on how to systematically approach literature evaluation. It describes how to identify the level and type of reference (tertiary, secondary, primary), and provides tips for evaluating different aspects of clinical studies, such as the objective, subjects, treatment administration, setting, methods, controls, and data analysis. The document also discusses how the FDA communicates important drug safety information to healthcare professionals and the public.
UNC Eshelman School of Pharmacy Highlights
The document describes the UNC Eshelman School of Pharmacy as a recognized leader in pharmacy education, practice, and research. It provides details on its academic programs, research centers focused on drug discovery and development, and partnerships within UNC and with outside organizations. The School has over 100 faculty conducting research across therapeutic areas from discovery through clinical practice, and seeks to enhance its research enterprise through partnerships with industry.
What Can You Do at the UNC Eshelman School of Pharmacy
The document summarizes what students can do at the UNC Eshelman School of Pharmacy, including joining a top-ranked PharmD program, learning from renowned faculty, and developing skills to provide patient-centered care in various healthcare settings. Students also have opportunities to innovate, pursue research interests, collaborate with organizations, and explore career paths in academia, industry, government, and non-profits.
Pharmacoepidemiology
Pharmacoepidemiology is the study of effects of drugs in large numbers of people.
Epidemiologic Study Designs, Reasons to perform Pharmacoepidemiology studies, Users of pharmacoepidemiology and Role of Pharmacists & other Public Health Practitioners in Pharmacoepidemiology are discussed in this presentation.
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
How Medication Adherence and Specialty Drugs Impact Employer Healthcare CostsHEALTHWORKS by Carolinas Healthcare System
This Atrium Health study and pilot program revealed healthcare savings potential resulting from a tailored approach to medication adherence and specialty drug programs.
Rational use of medicines for BPH
The document discusses rational use of drugs and strategies to promote rational use. Rational use means using the right drug, for the right indication, at the right dose and duration, for the right patient. Irrational use can lead to ineffective treatment, adverse drug events, increased resistance, and costs. Common causes of irrational use include lack of information, diagnostic uncertainty, patient demands, and promotional activities. Strategies to promote rational use include educational programs for providers, printed materials, media campaigns, essential drug lists, structured order forms, generic substitution, and regulating promotions. Rational prescribing involves defining the problem, setting objectives, selecting strategies, writing prescriptions, and monitoring treatment.
14ab1t0009 newsletter
This document provides guidance on creating an effective newsletter for a hospital pharmacy. It defines a newsletter as a periodic bulletin issued to members of an organization. The aims of the pharmacy newsletter are to transmit information and communicate decisions made by the Pharmacy and Therapeutics Committee. The newsletter should contain updates on new drugs, safety information, guidelines, and decisions regarding the drug formulary and utilization reviews. When creating the newsletter, special attention should be paid to selecting an informative title, including relevant content sections, using an easy-to-navigate format, and wide distribution to medical staff and departments. Photos and layout should have a professional quality while keeping paragraphs and articles concise.
Essential drug concept and rational use of medicines
The document discusses the concept of essential medicines and rational use of medicines. It defines essential medicines as those that satisfy the priority healthcare needs of the population based on criteria such as public health relevance, efficacy, safety and cost-effectiveness. Rational use requires patients receive appropriate medications for an adequate time at lowest cost. Irrational use can lead to ineffective and unsafe treatment, increased morbidity and mortality, and unnecessary costs. Strategies to promote rational use include education and training of healthcare providers, use of treatment guidelines, and ensuring availability of essential medicines.
Essential drug concept and rational use of medicines
This document discusses the essential medicine concept and rational use of medicines. It defines essential medicines as those that meet the health needs of a population based on effectiveness, safety, and cost. Essential medicine lists include generic drug names, dosage forms, strengths, and indications. Irrational medicine use can lead to ineffective or unsafe treatment, increased costs and resistance. Rational use means using medicines appropriately for each patient's needs in terms of drug choice, dosage, duration, and cost. The document outlines various educational, managerial, regulatory and economic strategies to promote rational medicine use.
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...Emmanuel Mosoti Machani
Dr. Julius Ogato was aming the Ministry of Health Departmental Heads presenting at the 3rd HSDPF.
The presentation elicited interest from counties keen on adopting a single-use policy for health products and commodities. Cadth 2015 c6 final- hospital formularies decision-making process es
This document summarizes the findings of a survey on collaboration between hospital formulary decision-making committees and provincial public drug plans in Canada. The survey found that most respondents considered public drug plan formulary recommendations in their decisions. While some provinces have formal policies for alignment, others have informal processes. Challenges to alignment include differences in institutional roles and factors considered, as well as decision-making processes, implementation issues, and product types under review. Overall the survey identified ongoing efforts across Canada to improve collaboration and consistency between hospital and public drug plan formularies.
Rational drug use
The document discusses rational use of medicines and the role of pharmacists in promoting rational use. It defines rational use of medicines according to WHO as ensuring patients receive appropriate medicines based on their clinical needs at the lowest cost. Pharmacists can promote rational use by properly managing drug stocks, dispensing medications correctly with patient education, and participating in pharmacovigilance programs. The document also outlines several other strategies to improve rational use, including developing treatment guidelines, regulating drug promotion, and educating both healthcare providers and the public.
Pharmacoepidemiology
This document provides an introduction to pharmacoepidemiology. It defines pharmacoepidemiology as the study of drug use and effects in large populations. It discusses study designs used in pharmacoepidemiology including randomized trials, cohort studies, case-control studies, and case reports. Reasons for performing pharmacoepidemiology studies include fulfilling regulatory and legal obligations, assessing drug safety, and generating or testing hypotheses. Sources of data include spontaneous adverse event reporting, prescription databases, and electronic health records. The document also briefly discusses molecular pharmacoepidemiology, bioethics, pharmacoeconomics, and measuring quality of life outcomes.
Jens Heisterberg - Patient involvement in drug development and licensing
Forskningsseminar hos KORA: "Hvordan involverer vi patienter i medicinsk forskning – og hvad betyder det for forskningen?" Den 02.03.2017
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Orphan designation evaluated by the EMA’s Committee for Orphan Medicinal Products to qualify as an orphan medicine for a rare disease
Teresa alves - selling sickness 2010
The document discusses disease awareness campaigns by pharmaceutical companies in Europe. It notes that while EU law prohibits direct advertising of prescription drugs to the public, companies use unbranded campaigns to indirectly promote their products. Several case studies of campaigns are presented that stretch and violate ethical guidelines by inappropriately fear-mongering about diseases and implying the need for specific brand-name drugs without disclosing risks. The document calls for regulatory agencies to better screen such campaigns and ensure companies are not using social media for disguised drug advertising.
More Related Content
What's hot
HTA in France
The document discusses HTA processes in France for evaluating new medicines. The French HTA process involves evaluating clinical value (SMR), clinical added value (ASMR), target population size, cost-effectiveness and budget impact. Medicines can receive reimbursement from the national health fund based on these evaluations. The HTA process aims to reward medicines providing real medical progress based on improved efficacy, safety or convenience compared to existing options (ASMR) and being worth their cost (cost-effectiveness).
Rational use of medicine
Rational use of medicine aims to ensure patients receive appropriate medications based on their needs. Irrational use can occur when there is polypharmacy, unnecessary or incorrect medications, underuse of effective medicines, or unsafe drug use. This presentation identifies factors contributing to irrational use at the international, national, health systems, prescriber, dispensing, and patient levels. These include issues like drug promotion, regulations, infrastructure, education and adherence. Strategies to improve rational use involve educational programs for prescribers and patients, management techniques, economic approaches, and regulatory policies like essential drug lists and multi-disciplinary oversight bodies.
ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...
The document discusses using patient-reported outcome measures like health-related quality of life (HRQoL) to evaluate the benefits of drug therapy from the patient's perspective. While traditionally outcomes were measured clinically, there is a shift towards considering how patients feel treatment impacts their daily lives. The document outlines challenges in defining what constitutes a clinically significant change in HRQoL and proposes further refining measures and educating clinicians on appropriate HRQoL data use.
From Laboratory to Patient
This document outlines the process for providing scientific advice to medicine developers through the European Medicines Agency (EMA). It describes the following key steps:
1. Medicine developers submit questions to EMA regarding their medicine development plans. Experts from EMA and national regulators form teams to address the questions.
2. The teams provide responses and advice to help developers design studies that will generate robust evidence on a medicine's safety and effectiveness. This advice is non-binding and does not guarantee approval.
3. The advice aims to help developers avoid poorly-designed trials and instead generate strong data to support regulatory approval and access for patients. It can also encourage development of needed new medicines.
Vi-Med tool for medication review - Form 3 - English version
This document describes various types of drug-related problems (DRPs) that can occur in patient care. It lists and provides examples of unnecessary indication, non-conformity indication, missing indication, inappropriate dosage, improper administration mode, drug side effects, drug interactions, and insufficient drug monitoring. The document appears to be a form or checklist for pharmacists to document a DRP identified in a patient, the pharmacist's intervention to address it, and any follow-up on the outcome of the intervention.
Law update, march 2011
This document summarizes recent legal issues affecting the practice of pharmacy in North Carolina. It discusses proposed state bills on pharmacy technician responsibilities in hospitals and pharmacist vaccination authority. It also outlines recent statutes on drug donation programs and upcoming elections for the North Carolina Board of Pharmacy.
Clinical literature evaluation
This document discusses the importance of evaluating clinical literature and provides guidance on how to systematically approach literature evaluation. It describes how to identify the level and type of reference (tertiary, secondary, primary), and provides tips for evaluating different aspects of clinical studies, such as the objective, subjects, treatment administration, setting, methods, controls, and data analysis. The document also discusses how the FDA communicates important drug safety information to healthcare professionals and the public.
UNC Eshelman School of Pharmacy Highlights
The document describes the UNC Eshelman School of Pharmacy as a recognized leader in pharmacy education, practice, and research. It provides details on its academic programs, research centers focused on drug discovery and development, and partnerships within UNC and with outside organizations. The School has over 100 faculty conducting research across therapeutic areas from discovery through clinical practice, and seeks to enhance its research enterprise through partnerships with industry.
What Can You Do at the UNC Eshelman School of Pharmacy
The document summarizes what students can do at the UNC Eshelman School of Pharmacy, including joining a top-ranked PharmD program, learning from renowned faculty, and developing skills to provide patient-centered care in various healthcare settings. Students also have opportunities to innovate, pursue research interests, collaborate with organizations, and explore career paths in academia, industry, government, and non-profits.
Pharmacoepidemiology
Pharmacoepidemiology is the study of effects of drugs in large numbers of people.
Epidemiologic Study Designs, Reasons to perform Pharmacoepidemiology studies, Users of pharmacoepidemiology and Role of Pharmacists & other Public Health Practitioners in Pharmacoepidemiology are discussed in this presentation.
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
How Medication Adherence and Specialty Drugs Impact Employer Healthcare CostsHEALTHWORKS by Carolinas Healthcare System
This Atrium Health study and pilot program revealed healthcare savings potential resulting from a tailored approach to medication adherence and specialty drug programs.
Rational use of medicines for BPH
The document discusses rational use of drugs and strategies to promote rational use. Rational use means using the right drug, for the right indication, at the right dose and duration, for the right patient. Irrational use can lead to ineffective treatment, adverse drug events, increased resistance, and costs. Common causes of irrational use include lack of information, diagnostic uncertainty, patient demands, and promotional activities. Strategies to promote rational use include educational programs for providers, printed materials, media campaigns, essential drug lists, structured order forms, generic substitution, and regulating promotions. Rational prescribing involves defining the problem, setting objectives, selecting strategies, writing prescriptions, and monitoring treatment.
14ab1t0009 newsletter
This document provides guidance on creating an effective newsletter for a hospital pharmacy. It defines a newsletter as a periodic bulletin issued to members of an organization. The aims of the pharmacy newsletter are to transmit information and communicate decisions made by the Pharmacy and Therapeutics Committee. The newsletter should contain updates on new drugs, safety information, guidelines, and decisions regarding the drug formulary and utilization reviews. When creating the newsletter, special attention should be paid to selecting an informative title, including relevant content sections, using an easy-to-navigate format, and wide distribution to medical staff and departments. Photos and layout should have a professional quality while keeping paragraphs and articles concise.
Essential drug concept and rational use of medicines
The document discusses the concept of essential medicines and rational use of medicines. It defines essential medicines as those that satisfy the priority healthcare needs of the population based on criteria such as public health relevance, efficacy, safety and cost-effectiveness. Rational use requires patients receive appropriate medications for an adequate time at lowest cost. Irrational use can lead to ineffective and unsafe treatment, increased morbidity and mortality, and unnecessary costs. Strategies to promote rational use include education and training of healthcare providers, use of treatment guidelines, and ensuring availability of essential medicines.
Essential drug concept and rational use of medicines
This document discusses the essential medicine concept and rational use of medicines. It defines essential medicines as those that meet the health needs of a population based on effectiveness, safety, and cost. Essential medicine lists include generic drug names, dosage forms, strengths, and indications. Irrational medicine use can lead to ineffective or unsafe treatment, increased costs and resistance. Rational use means using medicines appropriately for each patient's needs in terms of drug choice, dosage, duration, and cost. The document outlines various educational, managerial, regulatory and economic strategies to promote rational medicine use.
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...Emmanuel Mosoti Machani
Dr. Julius Ogato was aming the Ministry of Health Departmental Heads presenting at the 3rd HSDPF.
The presentation elicited interest from counties keen on adopting a single-use policy for health products and commodities. Cadth 2015 c6 final- hospital formularies decision-making process es
This document summarizes the findings of a survey on collaboration between hospital formulary decision-making committees and provincial public drug plans in Canada. The survey found that most respondents considered public drug plan formulary recommendations in their decisions. While some provinces have formal policies for alignment, others have informal processes. Challenges to alignment include differences in institutional roles and factors considered, as well as decision-making processes, implementation issues, and product types under review. Overall the survey identified ongoing efforts across Canada to improve collaboration and consistency between hospital and public drug plan formularies.
Rational drug use
The document discusses rational use of medicines and the role of pharmacists in promoting rational use. It defines rational use of medicines according to WHO as ensuring patients receive appropriate medicines based on their clinical needs at the lowest cost. Pharmacists can promote rational use by properly managing drug stocks, dispensing medications correctly with patient education, and participating in pharmacovigilance programs. The document also outlines several other strategies to improve rational use, including developing treatment guidelines, regulating drug promotion, and educating both healthcare providers and the public.
Pharmacoepidemiology
This document provides an introduction to pharmacoepidemiology. It defines pharmacoepidemiology as the study of drug use and effects in large populations. It discusses study designs used in pharmacoepidemiology including randomized trials, cohort studies, case-control studies, and case reports. Reasons for performing pharmacoepidemiology studies include fulfilling regulatory and legal obligations, assessing drug safety, and generating or testing hypotheses. Sources of data include spontaneous adverse event reporting, prescription databases, and electronic health records. The document also briefly discusses molecular pharmacoepidemiology, bioethics, pharmacoeconomics, and measuring quality of life outcomes.
Jens Heisterberg - Patient involvement in drug development and licensing
Forskningsseminar hos KORA: "Hvordan involverer vi patienter i medicinsk forskning – og hvad betyder det for forskningen?" Den 02.03.2017
What's hot (20)
ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...
ARE WE USING THE RIGHT OUTCOME MEASURE TO ASCERTAIN PATIENT BENEFIT FROM DRUG...
Vi-Med tool for medication review - Form 3 - English version
Vi-Med tool for medication review - Form 3 - English version
What Can You Do at the UNC Eshelman School of Pharmacy
What Can You Do at the UNC Eshelman School of Pharmacy
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
Essential drug concept and rational use of medicines
Essential drug concept and rational use of medicines
Essential drug concept and rational use of medicines
Essential drug concept and rational use of medicines
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...
Cadth 2015 c6 final- hospital formularies decision-making process es
Cadth 2015 c6 final- hospital formularies decision-making process es
Jens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensing
Similar to Trigger Point – Self-medication: Patients in white coats
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Orphan designation evaluated by the EMA’s Committee for Orphan Medicinal Products to qualify as an orphan medicine for a rare disease
Teresa alves - selling sickness 2010
The document discusses disease awareness campaigns by pharmaceutical companies in Europe. It notes that while EU law prohibits direct advertising of prescription drugs to the public, companies use unbranded campaigns to indirectly promote their products. Several case studies of campaigns are presented that stretch and violate ethical guidelines by inappropriately fear-mongering about diseases and implying the need for specific brand-name drugs without disclosing risks. The document calls for regulatory agencies to better screen such campaigns and ensure companies are not using social media for disguised drug advertising.
2o OTC & Cosmetics Conference, Raymond Anderson
Ομιλία – Παρουσίαση: Raymond Anderson, President Commonwealth Pharmaceutical Association and Member of the Pharmacovigilance Risk Assessment Committee (PRAC) at EMA
«Best Practices to inform citizens on Self-medication»
Concept of essential medicines and rational use of medicines
This document discusses essential medicines and rational drug use. It defines essential medicines as those that meet the priority health care needs of the population based on efficacy, safety and cost-effectiveness. The WHO publishes a model list of essential medicines that is divided into core and complementary items. Rational drug use means using the appropriate medicine at the right dose for the correct duration. Promoting rational use involves training, continuing education, and formulary guidance. Irrational use increases costs and harms patients.
Final Self Medication In Croatia Du 26.5.07
This document discusses self-medication in Croatia, including an overview of self-medication worldwide and in Croatia specifically. It notes that over-the-counter (OTC) drugs make up 27% of drugs used in Croatia by unit. The role of pharmacists is expanding to include health consultation to help patients practice responsible self-medication. Future goals include increasing education of both medical professionals and patients about responsible OTC drug use and the differences between OTC drugs and dietary supplements.
research 1
- The document discusses a study that assessed the attitudes and behaviors of pharmacy professionals towards patient counseling in Awi Zone, North West Ethiopia.
- The study found that over half of respondents believed counseling is a shared responsibility between pharmacists and physicians. The main reason respondents cited for counseling was improved patient compliance.
- Lack of knowledge and confidence was the primary barrier preventing respondents from counseling patients more. Most respondents felt counseling promotes rational drug use.
Essential drug for B. Sc. Nursing 1st year students of BPKIHS
Essential drug for B. Sc. Nursing 1st year students of BPKIHSBP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
This document provides guidelines for physicians, pharmacists, nurses and medical auxiliaries on essential drugs. It includes an introduction by the Director of the World Health Organization's Essential Drugs and Other Medicines department, as well as sections on the editorial committee, contributors, preface, foreword, and use of the guide.Current Trends in Pharmacy Practice and Overview of (1).ppt
The document discusses current challenges in pharmacy practice in Ethiopia, including knowledge and skill gaps among professionals. It proposes strategies to improve practice through implementing patient-focused training, in-service clinical pharmacy training, and advancing clinical pharmacy services. Clinical pharmacy aims to shift the focus from drug products to patient care by applying pharmaceutical expertise to maximize drug efficacy and safety.
The Integration of Traditional and Complementary Medicine in Health Systems 2012
The Integration of Traditional and Complementary Medicine in Health Systems 2012Asian Food Regulation Information Service
This document discusses the integration of traditional and complementary medicine into health systems. It provides an overview of the World Health Organization's policies on this issue, including the Beijing Declaration which calls on governments to integrate traditional medicine into their national health care systems. The document also discusses different models of integration, from inclusive systems that recognize but have not fully integrated traditional medicine, to integrative systems where it is officially recognized and incorporated into all areas of health care provision.2016 11 17 aaps_337 denver vulto biosimilars interchangeability vs16k16agv
2016 11 17 aaps_337 denver vulto biosimilars interchangeability vs16k16agvErasmus University Medical Center
This document summarizes a presentation on biosimilars given in Europe. It discusses:
- The new drug development paradigm for biosimilars based on comparability rather than traditional clinical trials.
- Differences in biosimilar definitions and regulations across European countries.
- The importance of national regulators' opinions in influencing biosimilar acceptance.
- Efforts to close the information gap between regulators, manufacturers, and healthcare professionals regarding biosimilars.
- Strategies to build trust in biosimilars among stakeholders like educating prescribers and involving patient organizations.Adherencia al Tratamiento. Dr. Antjefink Wagner
Adherencia al Tratamiento. Dr. Antjefink WagnerSociedad Latinoamericana de Alergia, Asma e Inmunología
The document discusses improving patient adherence to medical treatment through the coordinated efforts of multiple stakeholders. It describes how health literacy is essential for adherence and how patient advocacy empowers patients. It then provides examples of how physicians, nurses, pharmacists, insurers, family/friends, policymakers, pharmaceutical companies, and patient associations can help change patient behavior to increase adherence. The overall conclusion is that adherence requires advocacy initiatives from across healthcare to help patients comply with treatment recommendations.Health technology assessment
This document provides a summary of a report on Health Technology Assessment (HTA) in Europe. It discusses how HTA is increasingly influencing reimbursement decisions and pricing across multiple European countries. The report examines the role of HTA agencies in Germany, France, Italy, Spain, and the UK. Experts note both challenges and opportunities for harmonizing HTA approaches in Europe. They also discuss the roles of various stakeholders like drug manufacturers, payers, physicians, and patients in HTA and reimbursement outcomes.
The Role of the Pharmacy in Adherence Support
This document discusses the expanding role of pharmacists in supporting HIV treatment adherence. It provides examples of how pharmacists in Cote d'Ivoire, Kenya, and South Africa work to enhance adherence through patient education, integrated appointment and pill count systems, visual analogue scales to assess adherence, and task-shifting some responsibilities to peer educators. The document also presents case studies demonstrating pharmacist interventions around medication counseling, drug interactions, pediatric dosing, and adherence barriers.
0326 150514073330-lva1-app6892
The document discusses the role of pharmacists in achieving therapeutic efficacy and cost-effectiveness in the management of allergic rhinitis. It outlines that pharmacists can play a key role in providing professional advice for self-medication of intermittent and mild persistent allergic rhinitis using over-the-counter antihistamines. This can help ensure good disease control while reducing healthcare costs for individuals and health insurance funds. The document also discusses how pharmacist counseling is important for proper administration of medications and treatment monitoring to prevent inappropriate drug use.
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND
COST EFFECTIVENESS IN THE MANAGEMENT OF ALLERGIC RHINITIS
Community pharmacy
Community pharmacists play an important role in public health by ensuring the appropriate use of medications. They process prescriptions, provide clinical care and counseling to patients, monitor drug usage, and inform health professionals and the public about medications. Community pharmacists also produce some medications, advise on minor ailments, participate in health campaigns, and provide services to veterinary and agricultural practices. They are highly accessible health professionals who aim to promote the safe, effective, and rational use of drugs.
Opportunities for Pharmacy Practice Research in Community Setting
The document discusses opportunities for pharmacy practice research in community settings. It begins by outlining the changing role of pharmacists from product-focused to patient-centered care. There is a need for pharmacy practice research in community settings to optimize medication use, support self-care, and improve health outcomes. The presentation then describes development of a clinical tool called STARZ-DRP, which is a step-by-step approach for minor illness consultation and triaging decisions in community pharmacies. A study was conducted to evaluate STARZ-DRP which found it improved identification of drug-related problems and referral decisions compared to usual care.
Safety Monitoring of Natural Medicine
This document provides guidelines for monitoring the safety of herbal medicines. It discusses the importance of including herbal medicines in pharmacovigilance systems to understand adverse effects from combined herbal and conventional medicine use. Sources of safety reports include healthcare professionals, consumers, hospitals, and manufacturers. National regulatory agencies are responsible for communicating safety information through various channels to facilitate safe and effective herbal medicine use.
10276813.ppt
Avastin, Lucentis & Zaltrap, Eylea discuss several drugs used to treat wet age-related macular degeneration: Avastin, Lucentis, Eylea, and Zaltrap. The document outlines the mechanisms and approval process for each drug, compares their dosing and prices, and discusses controversies around off-label use of Avastin versus the higher-priced approved drugs.
An introduction to the EMA
The document discusses the role of patients, healthcare professionals, and academics in the European Medicines Agency's (EMA) process of approving medicines in the European Union. It describes how patients and patient organizations can provide input and expertise at various stages of the medicine development and review process. This includes involvement in scientific committees, evaluation of product information for patients, and review of safety communications. While patient participation has increased in recent years, challenges remain around representation, measuring impact, and ensuring comprehensive training. The EMA also facilitates collaboration with healthcare professionals and academics to enhance regulation and research.
Similar to Trigger Point – Self-medication: Patients in white coats (20)
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Orphan Medicinal Product Designation in the EU - By Compliance Global Inc.
Concept of essential medicines and rational use of medicines
Concept of essential medicines and rational use of medicines
Essential drug for B. Sc. Nursing 1st year students of BPKIHS
Essential drug for B. Sc. Nursing 1st year students of BPKIHS
Current Trends in Pharmacy Practice and Overview of (1).ppt
Current Trends in Pharmacy Practice and Overview of (1).ppt
The Integration of Traditional and Complementary Medicine in Health Systems 2012
The Integration of Traditional and Complementary Medicine in Health Systems 2012
2016 11 17 aaps_337 denver vulto biosimilars interchangeability vs16k16agv
2016 11 17 aaps_337 denver vulto biosimilars interchangeability vs16k16agv
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
Opportunities for Pharmacy Practice Research in Community Setting
Opportunities for Pharmacy Practice Research in Community Setting
More from inemet
EUFEPS and European Initiatives in Pharmaceutical Sciences
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Legal requirements for generics and abridged products and bioequivalence
This document summarizes key concepts related to legal requirements for generic and abridged drug products, including definitions, regulations, bioequivalence, and pros and cons of generic drugs. It discusses definitions of innovator products, generic medicines, pharmaceutical equivalence and alternatives. It also covers requirements for generic drug applications, marketing authorizations, and the need to demonstrate bioequivalence to the reference product through appropriate studies. Guidelines for bioavailability and bioequivalence studies from regulatory authorities are mentioned.
Significance of BA/BE studies in drug research and evaluation of different as...
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
The role of dissolution in the demonstration of bioequivalence
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Future trends and perspectives in modern pharmaceutical biotechnology
1. The document discusses trends and perspectives in modern pharmaceutical biotechnology, including the development from traditional biotechnology using secondary metabolites to modern biotechnology using recombinant DNA techniques.
2. It describes the transition from first generation biopharmaceuticals that mimic natural proteins to second generation biopharmaceuticals with improved properties through techniques like PEGylation, protein engineering, and protein fusions.
3. The introduction of biosimilars, advances in gene therapy and tissue engineering, and progress toward personalized drug therapy are also discussed as important trends and future perspectives in the field.
Bioavailability and bioequivalence – problems and pitfalls
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
The truth between the lines – Community pharmacists in improving the health o...
Community pharmacists can play an important role in improving public health by providing evidence-based advice and services. This includes promoting healthy behaviors, preventing disease, identifying health issues, and supporting those with long-term conditions. The evidence shows pharmacists are well-positioned for this work given their accessibility and the frequent contact the public has with pharmacies. However, pharmacists need more support to take a holistic, proactive approach to public health rather than just reacting to issues related to medicines. Priority areas for pharmacists to provide brief lifestyle advice include physical activity, weight management, diet, nutrition, smoking, and alcohol.
POSTGENETICS MEDICINE
PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com
Sightseeing Pharmacy practice - The way forward
The document discusses future options for community pharmacy practice and trends influencing those options. It outlines four potential models for future pharmacy practice: a shop model focused on over-the-counter sales; a commercial chain model with limited professional services; a "MacPharmacy" model focused only on fast-moving prescriptions; and a professional practice/clinic model providing complex patient care services in collaboration with other health providers. Each model is described and questions are posed about how each option would impact patients, the profession, and monopoly over pharmacy services. Implementation of new practice models is discussed as requiring change management and addressing barriers through a stepwise project plan.
EU telematics in the regulation of pharmaceuticals
The document discusses EU Telematics, which are IT systems developed at the European level to support the regulation of medicinal products across the European Union and European Economic Area. It describes several key IT systems, including EudraCT for clinical trials, EudraVigilance for monitoring adverse drug events, EudraPharm for product information, and EudraGMP for good manufacturing practice inspections. These systems were created to facilitate information sharing, avoid duplication, and support the regulatory process for medicinal products throughout their lifecycle across multiple countries.
Generics and Biogenerics
The document summarizes trends in research and development of generic drugs in the global pharmaceutical industry. It provides an overview of historical developments in generic drug maker PLIVA dating back to 1928, and its combination with Barr Group in 2006 to form a global generic pharmaceutical company. It also discusses trends in the generic drug market, strategies for differentiation, and key factors for success in generic drug research and development, emphasizing the importance of speed, intellectual property positioning, and internal API development capabilities.
Pharmacovigilance Workshop
The document outlines a pharmacovigilance workshop, including definitions of pharmacovigilance, the need for monitoring drug safety post-approval, and the pharmacovigilance system process of collecting, evaluating and taking action on adverse drug reactions. The workshop introduction discusses educational activities in Croatia to increase healthcare professional reporting of adverse reactions.
Making knowledge matter: The Skills Inventory and the Competency Maps
This document discusses the importance of knowledge and skills for economic life. It introduces the concepts of a skills inventory and competency maps for assessing knowledge dimensions and mapping competencies. Various experts are quoted on topics like learning, knowledge, and skill development.
Pharmacy in croatia - A short overview
Croatia has a population of 4.4 million with 978 community pharmacies. The pharmacy network is regulated based on geographic and demographic criteria. Pharmacists must obtain a license through education and training. Continuing education is required to renew licenses every six years. Key challenges include incomplete legislation, delays in medicine reimbursement, and a lack of rural pharmacies.
Pharmacy Global Track(s)
The document discusses three principles for European community pharmacy: monopoly on distributing medicine, ownership of pharmacies restricted to pharmacists, and geographical distribution of pharmacies. It then examines how the political, economic, and scientific landscape has changed since these principles were established. Finally, it argues that knowledge and the ability to apply knowledge will be key to addressing modern healthcare challenges in both developing and affluent countries.
PharmaCon 2007 Presentation
The document announces the PharmaCon 2007 European Congress on the Future of Pharmacy which will take place from May 22-27, 2007 in Dubrovnik, Croatia. The congress will bring together stakeholders in pharmacy including students, professionals, and industry. It will feature a program, speakers, an expo and job fair, and social events. Dubrovnik is noted as a top tourist destination that will provide attendees an opportunity to learn and network as well as enjoy the city.
Anaphylactic reactions
Anaphylactic and anaphylactoid reactions are severe allergic reactions that can be life-threatening. Anaphylactic reactions are caused by immunoglobulin E or G antibodies responding to a previously encountered antigen. Anaphylactoid reactions have similar symptoms but are caused by non-antibody related mechanisms during first exposure. Common allergens that can trigger these reactions include foods, insect stings, pollen, medications like antibiotics, and contrast agents used in imaging. Treatment involves stopping exposure, monitoring vital signs, compensating fluid loss, and administering epinephrine which constricts blood vessels and stimulates the heart.
More from inemet (17)
EUFEPS and European Initiatives in Pharmaceutical Sciences
EUFEPS and European Initiatives in Pharmaceutical Sciences
Legal requirements for generics and abridged products and bioequivalence
Legal requirements for generics and abridged products and bioequivalence
Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalence
Future trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnology
Bioavailability and bioequivalence – problems and pitfalls
Bioavailability and bioequivalence – problems and pitfalls
The truth between the lines – Community pharmacists in improving the health o...
The truth between the lines – Community pharmacists in improving the health o...
EU telematics in the regulation of pharmaceuticals
EU telematics in the regulation of pharmaceuticals
Making knowledge matter: The Skills Inventory and the Competency Maps
Making knowledge matter: The Skills Inventory and the Competency Maps
Recently uploaded
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
Sattamatka.satta.matka.satta matka.kalyan weekly chart.kalyan chart.kalyan jodi chart.kalyan penal chart.kalyan today.kalyan open.fix satta.fix fix fix Satta matka nambarThe Steadfast and Reliable Bull: Taurus Zodiac Sign
Explore the steadfast and reliable nature of the Taurus Zodiac Sign. Discover the personality traits, key dates, and horoscope insights that define the determined and practical Taurus, and learn how their grounded nature makes them the anchor of the zodiac.
欧洲杯投注-欧洲杯投注外围盘口-欧洲杯投注盘口app|【网址🎉ac22.net🎉】
【网址🎉ac22.net🎉】欧洲杯投注是体育博彩和在线赌场之一，得益于UKGC的三项许可。 成立之初是三名博彩公司将40家博彩商店的合并的结果，共同创建一家名为欧洲杯投注的公司。 欧洲杯投注在线赌场为游戏爱好者提供了300多种游戏，其中200多种老虎机，其他游戏包括二十一点，轮盘，真人荷官和真人赌场等。
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka Indian satta Matka Dpboss Matka Kalyan Chart Matka Boss otg matka Guessing Satta Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
The latest Heat Pump Manual from Newentide
𝐔𝐧𝐯𝐞𝐢𝐥 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐄𝐧𝐞𝐫𝐠𝐲 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐰𝐢𝐭𝐡 𝐍𝐄𝐖𝐍𝐓𝐈𝐃𝐄’𝐬 𝐋𝐚𝐭𝐞𝐬𝐭 𝐎𝐟𝐟𝐞𝐫𝐢𝐧𝐠𝐬
Explore the details in our newly released product manual, which showcases NEWNTIDE's advanced heat pump technologies. Delve into our energy-efficient and eco-friendly solutions tailored for diverse global markets.
AI Transformation Playbook: Thinking AI-First for Your Business
I dive into how businesses can stay competitive by integrating AI into their core processes. From identifying the right approach to building collaborative teams and recognizing common pitfalls, this guide has got you covered. AI transformation is a journey, and this playbook is here to help you navigate it successfully.
Discover the Beauty and Functionality of The Expert Remodeling Service
Unlock your kitchen's true potential with expert remodeling services from O'Brien Group Inc. Transform your space into a functional, modern, and luxurious haven with their experienced professionals. From layout reconfiguration to high-end upgrades, they deliver stunning results tailored to your style and needs. Visit obriengroupinc.com to elevate your kitchen's beauty and functionality today.
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...Ksquare Energy Pvt. Ltd.
During the budget session of 2024-25, the finance minister, Nirmala Sitharaman, introduced the “solar Rooftop scheme,” also known as “PM Surya Ghar Muft Bijli Yojana.” It is a subsidy offered to those who wish to put up solar panels in their homes using domestic power systems. Additionally, adopting photovoltaic technology at home allows you to lower your monthly electricity expenses. Today in this blog we will talk all about what is the PM Surya Ghar Muft Bijli Yojana. How does it work? Who is eligible for this yojana and all the other things related to this scheme?Business storytelling: key ingredients to a story
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
9356872877Sattamatka.satta.matka.satta matka.kalyan weekly chart.kalyan chart.kalyan jodi chart.kalyan penal chart.kalyan today.kalyan open.fix satta.fix fix fix Satta matka nambar.Digital Transformation Frameworks: Driving Digital Excellence
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This presentation is a curated compilation of PowerPoint diagrams and templates designed to illustrate 20 different digital transformation frameworks and models. These frameworks are based on recent industry trends and best practices, ensuring that the content remains relevant and up-to-date.
Key highlights include Microsoft's Digital Transformation Framework, which focuses on driving innovation and efficiency, and McKinsey's Ten Guiding Principles, which provide strategic insights for successful digital transformation. Additionally, Forrester's framework emphasizes enhancing customer experiences and modernizing IT infrastructure, while IDC's MaturityScape helps assess and develop organizational digital maturity. MIT's framework explores cutting-edge strategies for achieving digital success.
These materials are perfect for enhancing your business or classroom presentations, offering visual aids to supplement your insights. Please note that while comprehensive, these slides are intended as supplementary resources and may not be complete for standalone instructional purposes.
Frameworks/Models included:
Microsoft’s Digital Transformation Framework
McKinsey’s Ten Guiding Principles of Digital Transformation
Forrester’s Digital Transformation Framework
IDC’s Digital Transformation MaturityScape
MIT’s Digital Transformation Framework
Gartner’s Digital Transformation Framework
Accenture’s Digital Strategy & Enterprise Frameworks
Deloitte’s Digital Industrial Transformation Framework
Capgemini’s Digital Transformation Framework
PwC’s Digital Transformation Framework
Cisco’s Digital Transformation Framework
Cognizant’s Digital Transformation Framework
DXC Technology’s Digital Transformation Framework
The BCG Strategy Palette
McKinsey’s Digital Transformation Framework
Digital Transformation Compass
Four Levels of Digital Maturity
Design Thinking Framework
Business Model Canvas
Customer Journey Map
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
2022 Vintage Roman Numerals Men Rings
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Lithium Will Power Us For The Next 50 Years And Then Robots: Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Recently uploaded (20)
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
Dpboss Matka Guessing Satta Matta Matka Kalyan panel Chart Indian Matka Dpbos...
The Steadfast and Reliable Bull: Taurus Zodiac Sign
The Steadfast and Reliable Bull: Taurus Zodiac Sign
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
AI Transformation Playbook: Thinking AI-First for Your Business
AI Transformation Playbook: Thinking AI-First for Your Business
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Digital Transformation Frameworks: Driving Digital Excellence
Digital Transformation Frameworks: Driving Digital Excellence
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Kirill Klip GEM Royalty TNR Gold Lithium Presentation
Trigger Point – Self-medication: Patients in white coats
- 1. Pharmacon 2007 European Congress on Future of Pharmacy New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education Dubrovnik – 26 May 2007 Trigger Point – Self-medication: Patients in white coats Dr Hubertus Cranz Director General Association of the European Self-Medication Industry (AESGP) 7, avenue de Tervuren – B-1040 Brussels – Belgium Tel: +32 2 735 51 30 Fax: +32 2 735 52 22 info@aesgp.be www.aesgp.be
- 2. Total Non Prescription Bound Prescription Bound * * prescription necessary by law to receive a product Prescribed by a medical doctor Bought without Prescription Structure of the pharmaceutical market So called Semi- Ethicals Self-Medication
- 3. STUDY ON EUROPEAN CONSUMER ATTITUDES ON SELF MEDICATION PRODUCTS PURCHASED AT PHARMACIES
- 5. 20 pharmacies (urban/suburb) in each of 6 European countries were selected for the study. IPSOS staff interviewed, by pen and paper questionnaires, 1,268 people who purchased a self medication product as they exited those pharmacies: Sampling error at 9 5 % significance at total level E(1268)= +/- 2.8%; E( 2 00)=+/- 7 % in each country .
- 13. Cooperation with Pharmacists PGEU = Pharmaceutical Group of the European Union, umbrella organisation of Community pharmacists in Europe Update of the PGEU/AESGP Charter of Collaboration 2004 PGEU/AESGP Workshop “How appropriate presentation of non-prescription medicines enhances the role of the pharmacist” 2002 PGEU/AESGP Collaboration in TESEMED, an EU sponsored project on telematic systems for responsible self-medication in pharmacies 1998-2000 Joint symposium on the visibility of non-prescription medicines in pharmacies 1998 Joint meetings with the representation of medical doctors 1996 & 1997 First joint symposium PGEU/AESGP 1994 PGEU/AESGP Charter of Collaboration signed 1993
- 14. Cooperation with Medical Doctors CPME = Comité Permanent des Médecins Européens / Standing Committee of European Doctors, umbrella organisation of medical doctors in Europe Joint project with the World Medical Association: “From Patient to Self-Health Manager” 2006 Involvement of CPME in the AESGP study on new indications for self-medication and related information medicines 2001-2002 Joint brochure with CPME with the support of the European Commission 1997
- 19. THE ECONOMIC AND PUBLIC HEALTH VALUE OF SELF-MEDICATION AESGP study on the Economic and Public Health Value of Self-Medication http://www.aesgp.be/ephv/2004study.pdf